Stock Traders Buy Large Volume of Ariad Pharmaceuticals Put Options (ARIA)
Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) saw some unusual options trading on Thursday. Stock traders bought 4,536 put options on the stock, American Banking and Market News reports. This is an increase of approximately 108% compared to the typical volume of 2,180 put options.
Several analysts have recently commented on the stock. Analysts at William Blair cut their price target on shares of Ariad Pharmaceuticals from $26.00 to $7.00 in a research note to investors on Thursday. They now have an “outperform” rating on the stock. Separately, analysts at RBC Capital cut their price target on shares of Ariad Pharmaceuticals from $28.00 to $9.00 in a research note to investors on Thursday. They now have an “outperform” rating on the stock. Finally, analysts at Guggenheim cut their price target on shares of Ariad Pharmaceuticals from $28.00 to $10.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $13.63.
Ariad Pharmaceuticals (NASDAQ:ARIA) traded down 7.20% on Thursday, hitting $5.41. The stock had a trading volume of 26,888,108 shares. Ariad Pharmaceuticals has a 52-week low of $4.00 and a 52-week high of $25.40. The stock’s 50-day moving average is $19.16 and its 200-day moving average is $18.46. The company’s market cap is $1.001 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.40) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter last year, the company posted ($0.31) earnings per share. Ariad Pharmaceuticals’s revenue was up 4302.5% compared to the same quarter last year. Analysts expect that Ariad Pharmaceuticals will post $-1.64 EPS for the current fiscal year.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.